• The study was conducted in Argentina, Australia, Denmark, Canada, New Zealand, France and Scotland.

• The AESI list was specified by the Safety Platform for Emergency vACcines (SPEAC), following the roll-out of COVID-19 Vaccines in 2020.

• The researchers estimated the Observed/Expected ratio of selected AESI retrospectively, across certain risk intervals.

• More than 99 million individuals participated in the study.

• The potential vaccine safety signals were prioritized for the following vaccines based on a higher OE ratio:

1. ChAdOx1 vaccine for Guillain-Barre syndrome, cerebral venous sinus thrombosis, pericarditis and myocarditis

2. mRNA-1273 vaccine for Acute disseminated encephalomyelitis, pericarditis and myocarditis

3. BNT162b2 vaccine for pericarditis and myocarditis

• The present study provides stronger evidence of the previously identified rare side effects.

• Although the global generalizability of the results is higher, the result’s applicability to the Indian population is still questionable.

Click here to read more.